baloxavir marboxil 被批准用于流感暴露后预防
baloxavir marboxil 获批适应症在美国和欧洲已扩大至包括 12 岁及以上患者的流感暴露后预防。
baloxavir marboxil 对于暴露后预防的安全性和有效性，在一项 2018-2019 流行季于日本进行的多中心、双盲、随机、安慰剂对照试验中得到支持。
参与者以 1:1 比例分组，分别接受单剂量 baloxavir marboxil 和安慰剂。试验主要终点为 10 天内通过逆转录聚合酶链反应检测证实临床流行性感冒。
研究发现，在 baloxavir marboxil 组中，参与者发生临床流行性感冒的比例显著低于安慰剂组（1.9％ 和 13.6％）（调整后风险比 0.14；95％ 置信区间 [confidence interval, CI] 0.06 至 0.30；P<0.001）。两组在试验期间报告的不良事件发生率相似（baloxavir marboxil 组为 22.2％，安慰剂组为 20.5％）。
baloxavir marboxi 既往被批准用于 12 岁及以上，出现症状不超过 48 小时的非复杂性流行性感冒治疗。
更新原始来源external link opens in a new window
小结
定义
病史和体格检查
诊断性检查
治疗流程
撰稿人
作者
Staff Physician
Department of Pulmonary, Allergy and Critical Care
Cleveland Clinic
Cleveland
OH
利益声明
CR declares that she is on Advisory boards for CSL Behring and Speakers Bureau Biocryst.
同行评议者
Associate Professor
Medical Director of Infection Control
Infectious Disease
Department of Medicine
SUNY Upstate Medical University
Syracuse
NY
利益声明
WJ declares that he has no competing interests.
Associate Professor of Clinical Medicine and Environmental Health Sciences
Columbia University College of Physicians and Surgeons
New York
NY
利益声明
RLM declares that she has no competing interests.
Chief
SUNY Buffalo School of Medicine
Division Allergy and Immunology
Buffalo
NY
利益声明
MS declares that he has no competing interests.
Associate Professor
Department of General Practice and Primary Health Care
Ghent University
Ghent
Belgium
利益声明
ADS declares that she has no competing interests.
内容使用需遵循免责声明